Decision to list a range of single use instruments and VTE prevention devices supplied by BSN Medical Limited

What we're doing

We’re pleased to announce the approval of a listing agreement with BSN Medical Limited (“BSN”) for the supply of single use instruments and medical devices used in the prevention of venous thromboembolisms (VTE Prevention) to DHBs.

In summary, this will result in:

• Pharmaceutical Schedule listings for the Propax range of single use instruments and Comprinet Pro range of VTE Prevention products being supplied by BSN under a national agreement that all DHBs may purchase under (“Agreement”).
• DHBs continuing to be able to purchase other suppliers’ brands of single use instruments and VTE Prevention products as the Agreement is not for sole supply.
• The single use instruments and VTE Prevention products being available for DHBs to purchase at the PHARMAC negotiated prices, and terms and conditions from 1 March 2018.
• BSN providing training and education services that will be tailored to suit the needs of individual DHBs in formats and times as required by DHBs.
• Pricing for products in the Agreement, subject to any prior termination of the Agreement, is fixed until 1 March 2021.

Any changes to the original proposal?

This decision was subject to a consultation letter dated 12 January 2018. There have been no changes to the listing agreement as a result of consultation feedback. 

Who we think will be most interested

• DHB Staff
• Medical device suppliers
• Wholesalers

Details about this decision

In 2016 PHARMAC issued Requests for Proposals (RFPs) for single use instruments and VTE Prevention products. 

The RFPs requested proposals for non-exclusive national agreements for listing on the Pharmaceutical Schedule.

After completing the RFP evaluation processes, and consulting on the provisional Agreement reached with BSN, PHARMAC has decided to list BSN’s range of single use instruments and VTE Prevention products in Part III of Section H of the Pharmaceutical Schedule from 1 March 2018.

The financial impact of this Agreement on DHBs is $19,000 savings per annum, based on current usage levels. This consists of $13,000 savings per annum for single use instruments and $6,000 savings per annum for VTE Prevention products.

DHBs that purchase BSN’s single use instruments and VTE Prevention products must do so under the terms and conditions, and at the prices, included in the Agreement, from 1 March 2018.

DHBs can continue to choose which single use instruments and VTE Prevention products they purchase.

BSN’s single use instruments and VTE Prevention products are the latest that PHARMAC has decided to list on the Pharmaceutical Schedule. Further consultations in these categories are expected over the next few months.

The list of products will be available on PHARMAC's website from 1 March 2018, in both a PDF document and an Excel spreadsheet.

Our response to what you told us

We appreciate the time people took to respond to this consultation.

All consultation responses received by 2 February 2018 were considered in their entirety in making a decision to approve BSN’s provisional agreement.

A summary of the main themes raised in feedback and our responses to the feedback received are set out below:

If you have any questions about this decision, you can email us at enquiry@pharmac.govt.nz; or call our toll free number (9 am to 5 pm, Monday to Friday) on 0800 66 00 50.